Systemic therapy for unresectable advanced or metastatic pancreatic and midgut neuroendocrine tumours: Version 2
- MeSH Terms
Neuroendocrine Carcinoma, Gastroenteropancreatic neuroendocrine tumor, Phase 3 Clinical Trial, Phase 4 Clinical Trial, Randomized Controlled Trial, Guideline, Systematic Review, Quality Assessment, Adult, Octreotide, 177Lu-Dotatate, 90y-Dotatate
- Guideline Contact
- Roxanne Cosby; cosbyr@mcmaster.ca
- Keywords
- Guideline, Midgut Neuroendocrine Tumours, Pancreatic Neuroendocrine Tumours, Systemic Therapy, Systematic Review
- Date for Review
- The Program in Evidence-based Care (PEBC), Ontario Health (CCO) has an annual review process for each guideline. Guidelines are reviewed every fall, one year after they are completed
- Publication Date
- March 2024
- Date of Last Evidence Search
- October 30, 2023
- Methods Applied
- Evidence-based; Systematic review-based; External review; Evidence quality assessment; Patient/survivor/caregiver participation
- Publication Scope
- treatment
- Countries of Application
- Canada
- Guideline Publication Status
- Published
- Languages
- English
- Authors
- PEBC (Program in evidenced-based care)
- Publication Year
- 2024